PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT8001157

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
RUNSHENG LI	11/01/2022
WENTAO HUANG	11/01/2022

RECEIVING PARTY DATA

Name:	LANOVA MEDICINES LIMITED
Street Address:	2889 JINKE ROAD, BUILDING 10, ROOM 318
Internal Address:	CHAMTIME PLAZA
City:	SHANGHAI
State/Country:	CHINA
Postal Code:	201203

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	17685036

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 650-815-2600

Email: sdieu@sheppardmullin.com

SHEPPARD MULLIN RICHTER & HAMPTON LLP **Correspondent Name:**

Address Line 1: 650 TOWN CENTER DRIVE, 10TH FLOOR Address Line 4: COSTA MESA, CALIFORNIA 92626-1993

ATTORNEY DOCKET NUMBER:	70LG-322175-US
NAME OF SUBMITTER:	ALEX Y. NIE
SIGNATURE:	/Alex Y. Nie/
DATE SIGNED:	06/12/2023

Total Attachments: 3

507954022

source=Assignment(signed)_70LG-322175#page1.tif source=Assignment(signed)_70LG-322175#page2.tif source=Assignment(signed)_70LG-322175#page3.tif

REEL: 063920 FRAME: 0475

PATENT

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to singly and collectively as "ASSIGNOR") has sold, assigned, and transferred, and by these presents hereby sells, assigns, and transfers, unto

LANOVA MEDICINES LIMITED 2889 Jinke Road, Building 10, Room 318, Chamtime Plaza Shanghai 201203, China

(hereinafter referred to as "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for all countries in and to the inventions described and claimed in the patent applications and issued patents referenced in Schedule A as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent all countries for above-identified invention or inventions and all improvements and modifications thereof, (c) all Letters Patent which may issue from said applications in all countries, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, (e) all post-grant proceedings including but not limited to post-grant review, ex parte reexamination and inter partes review, and (f) the right to claim for any of said applications the full benefits and priority rights under the Patent Cooperation Treaty, the Paris Convention and any other international agreement; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY GRANTS ASSIGNEE the right to sue for past, present and future infringement, and the right to collect and receive any damages, royalties, or settlement for such past, present and future infringements and any and all causes of action relating to any of the inventions or discoveries described in this invention.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred



herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR/INVENTOR(S):

Signature:

Runshony Vi

Name: Runsheng Li

Signature: Winter

Name: Wentao Huang

Date: 2022-11.1

Signature:

Name: Ying Qin Zang

Date: ____ 20)2.|].|

ASSIGNEE:

Name Title:

Signature

Date:

SCHEDULE A

RECORDED: 06/12/2023

70I.G. 322175-WD PCT ANTI-CCR8 MONOCLONAL ANTIBODIES 70I.G. 322175-WD PCT ANTI-CCR8 MONOCLONAL ANTIBODIES 70I.G. 322175-WD PCT ANTI-CCR8 MONOCLONAL ANTIBODIES 70I.G. 322175-US US ANTI-CCR8 MONOCLONAL ANTIBODIES 70I.G. 322175-CN CN ANTI-CCR8 MONOCLONAL ANTIBODIES 70I.G. 322175-EP EP ANTI-CCR8 MONOCLONAL ANTIBODIES 70I.G. 322175-TW TW ANTI-CCR8 MONOCLONAL ANTIBODIES 70I.G. 322175-TW TW ANTI-CCR8 MONOCLONAL ANTIBODIES 70I.G. 322175-TW TW ANTI-CCR8 MONOCLONAL ANTIBODIES	Attorney Ref. No.	Aurisdiction	Title	Application Number	Filing Date	Patent Number	Issue
PCT US US AU AU TW							Date
UIS CN AU		D _a	ANTI-CCRS MONOCLONAL ANTIBODIES	PCT/CN2020/121494	10/16/2020		
US CN AU			AND USES THEREOF				
US ON AU		D _d	ANTI-CCR8 MONOCLONAL ANTIBODIES	PCT/CN2021/122994	11/11/2021		
CN CN AU	;		AND USES THEREOF				
CN AU		0.05	ANTI-CCR2 MONOCLONAL ANTIBODIES	17/685,036	03/02/2022		
CN AU EP			AND USES THEREOF				
AU EP		20	ANTI-CCR3 MONOCLONAL ANTIBODIES	2021.80004559.X	10/11/2021		
EP TW			AND USES THEREOF				
ML M		AU	ANTI-CCR8 MONOCLONAL ANTIBODIES	2021277712	10/11/2021		
d3 WL			AND USES THEREOF				
W.L		d3	ANTI-CCR8 MONOCLONAL ANTIBODIES	21815351.8	10/11/2021		
TW			AND USES THEREOF				
ACTION OF A COMPANY		TVV	ANTI-CCRS MONOCLONAL ANTIBODIES	111103700	01/27/2022		
CIATE COLO CIESTO			AND USES THEREOF				



PATENT REEL: 063920 FRAME: 0478